Cinclus Pharma (CINPHA) - Total Liabilities
Based on the latest financial reports, Cinclus Pharma (CINPHA) has total liabilities worth Skr221.84 Million SEK (≈ $23.87 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See working capital to net assets of Cinclus Pharma to evaluate short-term liquidity relative to the company's equity base.
Cinclus Pharma - Total Liabilities Trend (2022–2025)
This chart illustrates how Cinclus Pharma's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see CINPHA current and non-current assets.
Cinclus Pharma Competitors by Total Liabilities
The table below lists competitors of Cinclus Pharma ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Chilwa Minerals Ltd
AU:CHW
|
Australia | AU$1.60 Million |
|
T7 Global Bhd
KLSE:7228
|
Malaysia | RM1.89 Billion |
|
Univentures Public Company Limited
BK:UV
|
Thailand | ฿22.02 Billion |
|
NTPM Holdings Bhd
KLSE:5066
|
Malaysia | RM484.30 Million |
|
Land Securities Group PLC
LSE:LAND
|
UK | GBX5.00 Billion |
|
TETHYS PETROLEUM LTD
F:TP21
|
Germany | €33.97 Million |
|
Multifiling Mitra Indonesia
JK:MFMI
|
Indonesia | Rp328.16 Billion |
|
Fiducial Office Solutions
PA:SACI
|
France | €48.70 Million |
Liability Composition Analysis (2022–2025)
This chart breaks down Cinclus Pharma's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Cinclus Pharma balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.30 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.52 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cinclus Pharma's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cinclus Pharma (2022–2025)
The table below shows the annual total liabilities of Cinclus Pharma from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr177.16 Million ≈ $19.07 Million |
+287.81% |
| 2024-12-31 | Skr45.68 Million ≈ $4.92 Million |
-73.32% |
| 2023-12-31 | Skr171.21 Million ≈ $18.43 Million |
+190.70% |
| 2022-12-31 | Skr58.90 Million ≈ $6.34 Million |
-- |
About Cinclus Pharma
Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in … Read more